Skip to main content
. 2021 Jun 30;8:616380. doi: 10.3389/fmed.2021.616380

Figure 5.

Figure 5

Forest plots of the objective response rate (ORR) based on (A) treatment and (B) bevacizumab dose (7.5 mg/kg and 15 mg/kg) from randomized controlled trials of bevacizumab added to standard chemotherapy, compared with chemotherapy alone, as first-line therapy in patients with advanced NSCLC.